

Parkinson's Disease: Between the Clinical Diagnostic Gap and Therapeutic Horizons

A Neuropsychological Study



Ouada fathi *

Abdelhamid Mehri University - Constantine 2,
Fathi.ouada@univ-constantine2.dz

Date of submission: 05/03/2026 Date of acceptance: 24/05/2026 Date of publication: 08/06/2026



Abstract:

Parkinson's disease is considered one of the most prominent neurodegenerative disorders that face significant challenges in diagnosis and treatment. The diagnostic challenge lies in the absence of precise biological tests, making the diagnosis reliant on clinical symptoms particularly motor symptoms such as tremors and bradykinesia, which may overlap with other diseases, complicating the diagnosis, especially in the early stages. On the therapeutic front medication remains the primary treatment to compensate for dopamine deficiency, but it causes side effects with prolonged use. Meanwhile, deep brain stimulation (DBS) offers partial solutions in advanced cases. Despite recent advancements, such as the use of neuroimaging and genetic techniques, the disease still lacks a curative treatment, necessitating continued research to improve diagnosis and develop more effective therapies.

Keywords: Parkinson's disease, neurological diagnosis, genetic techniques, dopamine deficiency.

Introduction:

Parkinson's Disease (PD) is the second most common neurodegenerative disorder among the elderly, following Alzheimer's disease, representing a significant challenge in contemporary neurology (Zarotti et al., 2021). Since its initial description by James Parkinson in 1817, our understanding of the clinical and pathological characteristics of the disease has evolved remarkably (Liza et al., 2024); however, diagnostic and therapeutic challenges remain persistent.

* Corresponding Author

Parkinson's Disease is characterized as a neurodegenerative disorder that manifests through a complex array of motor and non-motor symptoms. Despite significant progress in understanding the potential mechanisms of the disease, identifying biomarkers with sufficient precision for routine clinical use remains a challenge. Diagnosis primarily relies on clinical symptoms, which may be subtle in the early stages and often overlap with other neurological disorders. Consequently, clinicians depend heavily on clinical examinations and medical records to identify and monitor the disease, leading to substantial challenges during both the initial diagnosis and the tracking of disease progression (Arya et al., 2024).

Recent studies indicate that the disease affects numerous aspects of patients' daily lives, including difficulties in movement, balance, speech, and sleep, with the potential development of dementia in advanced stages (World Health Organization [WHO], 2023). Within the local context, specifically in Algerian society, estimates suggest a significant increase in the number of patients over the next twenty years (Kaddour Ali, 2016), necessitating increased attention toward developing more effective diagnostic and therapeutic strategies.

It is worth noting that the precise causes of the disease are still not fully understood; it is believed that a complex interaction between genetic and environmental factors plays a pivotal role in the disease's development. Although there is currently no definitive cure, ongoing advancements in pharmacological treatments and multidisciplinary therapeutic interventions offer increasing hope for improving the quality of life for patients.

This scientific paper aims to analyze the current diagnostic challenges of Parkinson's disease, while exploring promising therapeutic prospects and recent developments in early diagnosis and treatment. Furthermore, it seeks to provide a comprehensive vision for enhancing patient healthcare and developing more effective therapeutic strategies in light of recent scientific advancements.

1. Disease Definition and Prevalence:

Parkinson's Disease (PD) is a neurodegenerative disorder that affects the central nervous system, specifically targeting dopamine-producing neurons in the substantia nigra region of the brain. As noted by Arya et al. (2024), the disease is characterized by the intracellular accumulation of alpha-synuclein (α -synuclein) protein aggregates, also known

as Lewy bodies, in addition to the progressive degeneration of dopaminergic neurons in the substantia nigra. Since dopamine is essential for motor activity, its deficiency is the primary cause of the disease's motor symptoms, which include tremors, bradykinesia (slowness of movement), rigidity, and difficulties with walking or speech.

Regarding the prevalence of the disease, Carine et al. (2024) explained that Parkinson's disease is one of the most widespread neurodegenerative disorders globally, affecting approximately 1.04 million people in the United States and 6.1 million people worldwide. The incidence rate increases significantly with age; the prevalence is approximately 1% among individuals over the age of 60, rising to over 3% among those over 80. Furthermore, studies indicate that the annual incidence rate of the disease is about 0.012% for all age groups, increasing to 0.044% for individuals over 50. Notably, 25% of patients begin to exhibit symptoms before the age of 65.

have increased significantly over recent decades; global estimates in 2019 indicated that more than 8.5 million individuals were living with the disease. This resulted in 8.5 million Disability-Adjusted Life Years (DALYs), an 81% increase since 2000. Furthermore, it caused 329,000 deaths, representing an increase of nearly 100% over the same period.

With the growing elderly population in societies, projections suggest that the prevalence and incidence rates of Parkinson's disease could increase by more than 30% by 2030. This will pose a significant challenge to health, social, and economic systems at both local and global levels.

2. Symptoms of Parkinson's Disease:

Parkinson's disease is characterized by a combination of motor and non-motor symptoms that significantly impact patients' daily lives and the progression of the disease.

2.1. Motor Symptoms:

These include Rest Tremors, which are rhythmic oscillations that typically begin on one side of the body, particularly in the hands (e.g., the thumb and index finger); this is often described as a "pill-rolling" motion. These tremors appear during rest, diminish during voluntary movement, and disappear during sleep. As for Muscle Rigidity... Extra pyramidal Hypertonia manifests as constant resistance to passive movement.

Additionally, Akinesia is a primary symptom, referring to a deficit in initiating spontaneous movements and a decrease in the frequency of voluntary actions. This leads to the loss of automatic movements, such as arm swinging while walking and natural facial expressions (Hypomimia). Furthermore, Postural Instability appears in advanced stages, leading to frequent falls due to impaired balance and difficulty initiating steps, turning, or navigating obstacles (Dujardin & Defebvre, 2007).

2.2. Non-Motor Symptoms:

In addition to motor symptoms, Parkinson's patients suffer from a wide range of non-motor symptoms that significantly impact their quality of life. These include autonomic nervous system disorders, such as constipation, which affects 60% of patients compared to 20-30% of the general population. Furthermore, Orthostatic Hypotension—which leads to dizziness—becomes more prevalent as the disease progresses (Defebvre & Vérin, 2011; Azulay et al., 2017).

Furthermore, REM Sleep Behavior Disorder (RBD) is common among patients and is considered an early indicator of the disease, especially when coupled with anosmia (loss of smell) (Azulay et al., 2017). Patients also suffer from insomnia and excessive daytime sleepiness, which may be exacerbated by treatment (Defebvre & Vérin, 2011).

Other symptoms include neurogenic and muscular pain, such as burning or tingling sensations, which necessitate therapeutic adjustments (Azulay et al., 2017). On the other hand, depression and anxiety appear in many patients and may progress to dementia in advanced stages (Defebvre & Vérin, 2011). Early recognition of these non-motor symptoms contributes to improving patients' quality of life and managing the disease effectively.

3. Factors Leading to Parkinson's Disease:

The causative factors of Parkinson's Disease (PD) are multifaceted, involving a complex interplay of genetic, environmental, and neurochemical factors.

3.1. Aging and Loss of Dopaminergic Neurons:

One hypothesis suggests that Parkinson's disease may result from accelerated aging. Typically, aging leads to the progressive death of dopaminergic neurons and a reduction in dopamine levels within the basal ganglia. However, the pattern of neuronal loss in normal aging differs significantly from that observed in Parkinson's disease. Furthermore, the extra pyramidal symptoms that appear in the elderly do

not respond to L-dopa treatment, indicating that Parkinson's disease is not merely the result of accelerated aging (Dujardin & Defebvre, 2007, p. 62).

3.2. Environmental Toxins:

The hypothesis of an environmental toxic factor was proposed following the observation of Parkinson-like cases among drug users due to poisoning with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). The clinical and neuropathological characteristics of these cases closely resemble Parkinson's disease. Furthermore, epidemiological studies indicate a correlation between exposure to pesticides, such as rotenone and paraquat, and an increased risk of developing Parkinson's disease. Additionally, higher prevalence rates of early-onset Parkinson's disease have been noted in areas where well water is consumed. However, environmental factors interact with individual, and possibly genetic, predispositions (Dujardin & Defebvre, 2007, p. 62).

3.3. Genetic Predisposition:

Research demonstrates a clear genetic component in Parkinson's disease, supported by a family history of the disorder in 15–20% of cases. A higher risk of infection is observed among first-degree relatives of patients compared to the relatives of healthy individuals. Furthermore, twin studies show significant concordance between monozygotic (identical) twins, confirming the genetic role. Several genes contributing to the disease have been identified, including those encoding for alpha-synuclein (α -synuclein), Parkin, PINK1, and LRRK2. These genes can be inherited through various patterns, including autosomal dominant and autosomal recessive modes. Despite the critical importance of genetic factors, most cases of Parkinson's disease are sporadic, indicating a complex interaction between genetic and environmental factors in the disease's development (Dujardin & Defebvre, 2007, pp. 63-64).

3.4. Mechanisms of Neuronal Death:

Neuronal death in Parkinson's disease leads to the excessive production of free radicals, causing a state of oxidative stress. This results from increased free radical production due to dopamine breakdown, alongside a deficiency in protective systems, such as the enzymes that regulate the effects of these radicals. The damage to dopaminergic neurons in the mesencephalon (midbrain) varies, concentrating in areas that lack adequate defenses against oxidative stress.

These injuries lead to apoptosis (programmed cell death) as a result of several factors, such as damage to the mitochondrial respiratory chain,

increased iron levels, and the accumulation of abnormal proteins like alpha-synuclein (α -synuclein). Furthermore, the neuroimmune system is triggered through microglial activation, producing cytokines and free radicals that stimulate cellular signaling pathways leading to cell death (Dujardin & Defebvre, 2007, p. 64).

4. Neuropsychiatric and Cognitive Disorders Associated with Parkinson's Disease:

While Parkinson's Disease (PD) is primarily considered a motor disorder, its associated psychiatric symptoms are often overlooked. Patients with PD suffer from a diverse range of psychiatric disorders, including anxiety, depression, apathy, impulse control disorders, and, in some cases, psychosis. Anxiety is the most common among these disorders, affecting up to 55% of patients; it often manifests as Generalized Anxiety Disorder (GAD) or social phobia. Depression, on the other hand, affects up to 56% of patients and is frequently diagnosed as either mild depression or Major Depressive Disorder (MDD).

Additionally, approximately 40% of patients present with a comorbid diagnosis of both anxiety and depression. These psychiatric disorders can emerge at any stage of the disease's progression; they may even precede the formal diagnosis by several years and significantly impact health-related quality of life. While traditional understanding of psychiatric symptoms focused on neurobiological changes, recent research suggests that these symptoms result from a complex interaction between neurological, psychological, and social factors, depending on each individual's specific symptoms (Zarotti et al., 2021).

On the other hand, cognitive decline in Parkinson's disease ranges from Mild Cognitive Impairment (MCI) to Parkinson's Disease Dementia (PDD), significantly impacting daily functioning and quality of life. Early symptoms include deficits in executive functions, attention, and visuospatial abilities, which subsequently worsen to affect memory and other cognitive domains (Zhang et al., 2020).

5- Diagnostic Challenges

(Junaid et al., 2023) indicated that the diagnosis of Parkinson's Disease (PD) currently relies heavily on clinical assessments and neurological examinations aimed at detecting motor disorders. However, traditional diagnostic methods suffer from several critical drawbacks, most notably the absence of definitive biomarkers for the disease, which hinders the early diagnosis of this neurodegenerative condition. Additionally, there is

significant variability in disease manifestations among individuals, which may serve as another factor leading to misdiagnosis or delayed treatment.

Neuropsychiatric disorders represent a significant diagnostic and therapeutic challenge in Parkinson's Disease (PD), given the complex interplay between motor and non-motor clinical manifestations. Optimal management of these conditions necessitates periodic symptom assessment every 6–12 months, with the active involvement of caregivers who provide valuable insights into the functional impact of these symptoms on the patient.

Comprehensive diagnostic tools include the Movement Disorder Society Non-Motor Rating Scale (MDS-NMRS) and the Neuropsychiatric Inventory (NPI). To assess specific disorders such as depression, the Beck Depression Inventory-II (BDI-II) and the Geriatric Depression Scale (GDS-15) are utilized. For evaluating anxiety, the Parkinson Anxiety Scale (PAS) is employed, while apathy is assessed using the Apathy Scale. Regarding psychosis, the Parkinson Psychosis Questionnaire (PPQ) is used. Finally, for impulse control disorders, the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP) is applied.

Digital technologies have brought about a paradigm shift in the accuracy of clinical assessments by providing real-time symptom monitoring, enabling the collection of objective data on daily clinical fluctuations. This technological advancement contributes to enhancing therapeutic decisions and tailoring treatment to individual patient needs (Weintraub et al., 2022).

Recent studies indicate that Machine Learning (ML) is a promising approach for improving the early diagnosis of Parkinson's Disease by analyzing complex and diverse datasets, such as voice recordings, handwriting samples, brain imaging, and genetic data. Furthermore, patient medical histories are utilized to identify patterns that may lead to a diagnosis in the prodromal stage (before the onset of motor symptoms). This novel technology (ML) also aids in discovering intricate patterns within large datasets, thereby significantly contributing to the early detection of the disease.

Furthermore, Machine Learning (ML) can handle high-dimensional data and uncover hidden relationships that are difficult to identify using traditional statistical methods, thereby enhancing diagnostic accuracy and contributing to a deeper understanding of disease progression, with the potential to discover novel biomarkers. It is expected that these advancements in Machine Learning will bolster diagnostic precision and

open new horizons for understanding and treating Parkinson's Disease (Liza et al., 2024).

The treatment of neuropsychiatric symptoms in Parkinson's Disease (PD) is witnessing a notable delay compared to the advancements made in managing motor symptoms, creating an urgent need for comparable progress. The complexity of psychiatric symptoms is exacerbated by the absence of specialized services and PD-related barriers, such as mobility issues that limit the ability to attend weekly psychotherapy sessions. Furthermore, effective treatment necessitates specialized clinical expertise and multidisciplinary collaboration, while accounting for the intricate interplay between motor and non-motor symptoms (Weintraub et al., 2022).

Conventional pharmacological treatment includes the use of dopaminergic medications such as Levodopa and Carbidopa, which help increase dopamine production in damaged neurons, thereby improving motor symptoms. However, as the disease progresses, the efficacy of these drugs gradually declines, and high doses may exacerbate side effects. Additionally, MAO-B Inhibitors, COMT Inhibitors, and Anticholinergics are used as adjunctive therapeutic options. In certain cases, antipsychotic medications are administered to treat psychiatric symptoms. Nevertheless, long-term pharmacological treatment may lead to the accumulation of toxic Reactive Oxygen Species (ROS), causing additional neuronal damage and reducing therapeutic effectiveness (Tong, 2024).

Cognitive decline in Parkinson's Disease (PD) is associated with alterations in both cholinergic and dopaminergic systems in the brain. Although dopaminergic medications, such as Levodopa, may improve motor symptoms, they can have adverse effects on cognitive functions. For the treatment of Parkinson's Disease Dementia (PDD), cholinesterase inhibitors like Rivastigmine show limited benefits but do not constitute a definitive cure. Currently, there are no approved pharmacological treatments for Mild Cognitive Impairment (MCI), necessitating a multidisciplinary approach that encompasses cognitive training, physical activity, and the management of comorbidities to enhance the patient's quality of life (Zhang et al., 2020).

On the psychological level, studies highlight the importance of psychological interventions in improving patient outcomes. Cognitive Behavioral Therapy (CBT) is the most widely used approach and has proven effective in treating depression and sleep disorders; however, its efficacy in improving anxiety, quality of life, and Impulse Control Disorders (ICDs) remains uncertain. Additionally, mindfulness-based interventions, such as Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR), have been explored, but their results have been mixed, necessitating further research (Zarotti et al., 2021).

Regarding other psychological interventions, studies suggest that therapies such as Acceptance and Commitment Therapy (ACT), Psychodrama, and Behavioral Activation (BA) may be effective in addressing the psychological difficulties faced by Parkinson's patients. Furthermore, the study by (Zarotti et al., 2021) emphasized the importance of fostering psychological resilience in patients—an aspect that remains insufficiently explored.

Despite advancements in psychological treatments, challenges persist due to the complex progression of Parkinson's Disease, particularly with the emergence of symptoms such as hallucinations, which tend to increase as the disease advances. Research has highlighted the need to understand the impact of psychosocial factors on the onset of these symptoms. Generally, there is a pressing need for high-quality studies and Randomized Controlled Trials (RCTs) to evaluate the efficacy of these psychological interventions and improve patient outcomes (Weintraub et al., 2022; Zarotti et al., 2021).

The findings of these studies underscore the importance of integrating pharmacological and psychological treatments to ensure a comprehensive improvement in the clinical and mental health of Parkinson's patients, paving the way for the development of more effective, multidimensional therapeutic strategies.

Conclusion

Parkinson's Disease represents a complex challenge in neurology, given its increasing prevalence, diverse clinical manifestations, and the multifaceted nature of its underlying factors. Despite significant progress in understanding the disease mechanisms and developing various therapeutic strategies, diagnostic and therapeutic hurdles continue to impede a comprehensive improvement in managing the condition. Recent studies offer promising horizons through the employment of modern

technologies, such as Machine Learning, for early detection and biomarker analysis, paving the way for more precisely targeted therapeutic interventions.

On the therapeutic level, traditional pharmacological strategies remain the cornerstone, alongside rapid advancements in psychological and surgical treatments that enhance patients' quality of life. Nevertheless, maintaining a focus on the psychosocial aspects of the disease remains essential for ensuring the provision of comprehensive care.

In light of the growing challenges, there is a pressing need to intensify scientific research and develop healthcare infrastructure to bolster early diagnosis and provide advanced treatments. Furthermore, building community and psychological support networks can make a significant difference in improving the quality of life for those affected. As research and technological advancements continue, the future appears brighter in the face of this neurodegenerative disease.

Bibliography List:

- Arya, R., Haque, A. K. M. A., Shakya, H., et al. (2024). Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression. *International Journal of Molecular Sciences*, 25(22), 12379. <https://doi.org/10.3390/ijms252212379>
- Azulay, J.-P., Witjas, T., & Eusebio, A. (2017). Non-motor signs of Parkinson's disease [Les signes non moteurs de la maladie de Parkinson]. *Presse Médicale*, 46(2), 195-201. <https://doi.org/10.1016/j.lpm.2016.11.015>
- Azulay, J.-P., Witjas, T., & Defebvre, L. (2011). Non-motor signs [Signes non moteurs]. In L. Defebvre & M. Vérin (Eds.), *Parkinson's Disease [La maladie de Parkinson]* (pp. 65-80). Elsevier Masson.
- Carine, M., Rao, D. S., Devi, C. S., Khan, A., & Rao, R. (2024). A Review on Parkinson's Disease: Progressive Neurodegenerative Disease Identification. *International Journal of Pharmacy and Pharmaceutical Research (IJPPR)*, 30(10), 188-197.
- Dujardin, K., & Defebvre, L. (2007). *Neuropsychology of Parkinson's Disease and Related Syndromes [Neuropsychologie de la maladie de Parkinson et des syndromes apparentés]*. Elsevier Masson.
- Liza, I. A., Hasan, E., Haque, M. M., et al. (2024). Predictive Modeling and Early Detection of Parkinson's Disease Using Machine Learning. *Journal of Medical and Health Studies*, 5(4), 97-107. <https://doi.org/10.32996/jmhs.2024.5.4.12>
- Junaid, M., Ali, S., Eid, F., El-Sappagh, S., & Abuhmed, T. (2023). Explainable machine learning models based on multimodal time-series data for the early detection of Parkinson's disease. *Computer Methods and Programs in Biomedicine*, 234, 107495.
- Kadour, A. (2016). An Acoustic Study on Voice Disorders in Parkinson's Disease Patients in the Algerian Clinical Context. *Bouhouth*, 10(01), 289-307.
- Tong, J. (2024). The pathogenesis and treatment of Parkinson's disease. *Theoretical and Natural Science*, 47, 15-19.

-
- **Weintraub, D., Aarsland, D., Chaudhuri, K. R., et al. (2022).** The neuropsychiatry of Parkinson's disease: advances and challenges. *The Lancet Neurology*, 21(1), 89–102. [https://doi.org/10.1016/S1474-4422\(21\)00330-6](https://doi.org/10.1016/S1474-4422(21)00330-6)
 - **World Health Organization. (2023).** *Parkinson's Disease*. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/parkinson-disease>
 - **Zarotti, N., Eccles, F. J. R., Foley, J. A., et al. (2021).** Psychological interventions for people with Parkinson's disease in the early 2020s: Where do we stand?. *Psychology and Psychotherapy*, 94(3), 760–797. <https://doi.org/10.1111/papt.12321>
 - **Zhang, Q., Aldridge, G. M., Narayanan, N. S., Anderson, S. W., & Uc, E. Y. (2020).** Approach to cognitive impairment in Parkinson's disease. *Neurotherapeutics*, 17(4), 1628–1653. <https://doi.org/10.1007/s13311-020-00963-x>